In line with ORR data, when time to progression since therapy initiation was evaluated, SAMHD1 positive patients presented shorter TTP than SAMHD1 negative patients, for ovarian and NSCLC tumors (log rank function, p = 0.003 and p = 0.005, respectively). The gene discussed is SAMHD1; the disease is non-small cell lung carcinoma.